Hyponatremia
📧 Sign up to get email alerts when something new happens for Hyponatremia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2019-02-06Clinical Trial Update: Fractional Urate Excretion in Nonedematous Hyponatremia [NA]
A clinical trial evaluating fractional urate excretion in nonedematous hyponatremia was withdrawn. The study involved cerebral hyponatremia …
-
CLINICAL_TRIALS withdrawal · 2017-07-31Clinical Trial Update: A Trial of Tolvaptan in Children and Adolescent Subjects With Euvolemic and Hypervolemic Hyponatremia [Phase 3]
A Phase 3 trial of tolvaptan for euvolemic and hypervolemic hyponatremia in children and adolescents has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2017-06-14Clinical Trial Update: Outcome and Treatment Quality Study of Tolvaptan to Treat Hyponatremia in Patients With Heart Failure [Phase 4]
Phase 4 clinical trial evaluating tolvaptan for hyponatremia in heart failure has been terminated.
-
CLINICAL_TRIALS withdrawal · 2016-01-29Clinical Trial Update: Reexamining Hypotonic Intravenous Fluid Use [NA]
A clinical trial evaluating the use of hypotonic intravenous fluids for hyponatremia was withdrawn from the study database.
-
CLINICAL_TRIALS withdrawal · 2015-07-23Clinical Trial Update: Frequency and Origin of Dysnatremias in the Emergency Department
A clinical trial (NCT01326429) on the frequency and origin of dysnatremias in the emergency department has been withdrawn. Sponsors Insel Gr…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-03-06Clinical Trial Update: Safety and Efficacy of Conivaptan for the Correction of Hyponatremia in Neurological Patients [Phase 3]
Phase 3 trial evaluating conivaptan for correcting hyponatremia in neurological patients has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2010-11-23Clinical Trial Update: International, Multicenter, Open-Label and Randomized Withdrawal Study of Oral Lixivaptan in Heart Failure Patients With Chronic Hyponatremia [Phase 3]
An international Phase 3 trial evaluating oral lixivaptan for hypervolemic hyponatremia in heart failure patients has been withdrawn.
-
EMA withdrawal · 2008-05-28EMA Application withdrawn: Aquilda (satavaptan) — Sanofi-Aventis
The EMA withdrew the application for Aquilda (satavaptan) by Sanofi-Aventis for the treatment of hyponatremia.